|
BioWorld's executive-level report provides updates and insight on the emerging companies, R & D landscape, and recent investments that are defining China's burgeoning biotech industry. Plus, gain access to the China Biotechnology database!
BioWorld's China Biotech 2009 written by General Biologic of Shanghai and published by
BioWorld Today, provides an unprecedented look at new developments in biotechnology in China. How can outside firms tap into the exploding research pipeline in China? What about the Heparin scare? Where are the best opportunities for investment?
With China Biotech 2009, you will receive answers and information on the following current events and industry trends:
- Access to capital: Sources of funding/investment trends in the Chinese biotech sector
- Intellectual property: Impact of the new amendment to China's patent law
- Recent MNC moves: Updates on the China activities of the larger biotech companies as well as Big Pharma (including Pfizer, Sanofi-Aventis, AstraZeneca, GSK, Schering-Plough, Lilly, Novartis, Merck and J&J)
- Outsourcing update: Latest on the rapidly growing and expanding outsourcing sector including chemistry, biology, and preclinical players
- Special Reports on Shocks to the Market : the impact on China's biopharma industry of the Wenchuan earthquake, the Heparin recall and the Olympics
- Industry trends: Profiles of biofuels, stem cells, biologics/biosimilars, and more.
China Biotech 2009 is priced at $599, plus $17.95 in shipping and handling.
You will learn from a series of interviews with industry leaders in China who share their insight and perspective on key areas of China's biotech landscape. In addition, Case Studies probe the growth and strategy of five Chinese companies, examining their management, technologies, facilities, products, collaborations, strengths and weaknesses.
- Interviews with key industry leaders includes: Peter Zhang, co-founder of Shanghai GenePharma; James Wen, CEO of SynCores; Jing Lou, CEO of 3S Bio; and Patrice Bonzom, China GM of Crucell Biotech.
- Company profiles: China National Biotech Group, Beijing Tiantan Biological Products, Da An Gene, Biomics Biotechnologies, Shenogen Pharma Group.
Key financial metrics is also provided in China Biotech 2009 on the commercial side of the industry. Access to hard-to-get investment information is available, as well as trend analysis of various sectors and companies. Highlights of these table-focused sections include:
- Overseas IPO Results Involving Chinese Bio Companies
- VC Investments in China's Biotech and Pharma Industries
- Major Joint Venture/Wholly Foreign-Owned Enterprises in China
- China's Clinical Phase Pipeline Grouped by Innovation Class
- Sector Information on Biologics, Antibodies, Vaccines, Diagnostics, Agricultural Biotech and Biofuels.
China Biotechnology Database
Plus, purchasers of the report will receive free access to the General Biologics Biotech & RD database, a comprehensive service providing in-depth information on more than 400 of China's biotechnology companies!
China Biotech 2009 is a must-have resource for anyone contemplating doing business in China. Whether your goals are partnering, investing, outsourcing or licensing, this report is imperative if you want the most current information available on the ins-and-outs of this emerging biotech region.
This report can be purchased in print or PDF.
To view the table of contents, click here.
|
Print and PDF Version:
|
|
Report-Only Price: $599 + ($17.95 s&h)
|
Order Now
|
|
